

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Donald W. KUFE and Surender
KHARBANDA

Serial No.: 10/598,295

Filed: April 5, 2007

For: MUC1 ANTAGONIST ENHANCEMENT
OF DEATH RECEPTOR LIGAND-
INDUCED APOPTOSIS

Group Art Unit: 1635

Examiner: McGarry, Sean

Atty. Dkt. No.: GENU:006US

Confirmation No.: 2459

CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
September 23, 2010 Date	Steven L. Highlander

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. §1.116

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

Sir:

This is in response to the Office Action dated March 25, 2010, (the "Action"), for which the date for response is June 25, 2010. It is believed that no other fees are due in connection with this response; however, if any other fees are due under 37 C.F.R. §§ 1.16 to 1.21, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski L.L.P. Account No.: 50-1212/GENU:006US.

Amendments to the Claims begin on page 2 of this paper. **Remarks** begin on page 3.